[Oral cavity manifestations of gastroesophageal reflux disease].
The aim of the study was to investigate changes in the oral cavity and the gastroesophageal zone of the patients receiving rabeprazol, a proton pump inhibitor (PPI). The subjects were 88 patients with gastroesophageal reflux disease (GERD), who had changes in the oral cavity typical of this disease. The patients were divided into four groups. Group I included patients with non-erosive reflux disease; the other three groups were formed according to the degree of the severity of reflux esophagitis in accordance with Los Angeles classification of GERD: A, B, and C. The patients were administered rabeprazol as a PPI. The study found that oral cavity changes are associated with the degree of the gastroesophageal reflux. The study demonstrated high efficacy of rabeprazol in GERD patients with oral cavity changes.
Maev
I V
IV
Barer
G M
GM
Busarova
G A
GA
Pustovoĭt
E V
EV
Polikanova
E N
EN
Burkov
S G
SG
Gurenev
G L
GL
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004947:Esophagus / Q000378:metabolism; D005260:Female; D005500:Follow-Up Studies; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D009055:Mouth / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D064750:Rabeprazole; D012463:Saliva / Q000378:metabolism; D012720:Severity of Illness Index; D013280:Stomatitis / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D064750:Rabeprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole